title: Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.
authors.affiliation: Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.
authors.forename: Philip W
authors.initials: PW
authors.lastname: Kantoff
authors.affiliation: Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
authors.affiliation: Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.
authors.forename: Cesar
authors.initials: C
authors.lastname: Pico-Navarro
mesh_terms: D001691:Biological Therapy; D019496:Cancer Vaccines / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004311:Double-Blind Method; D005500:Follow-Up Studies; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000401:mortality* / Q000628:therapy*; D015203:Reproducibility of Results; D013223:Statistics as Topic; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; C588274:PROSTVAC; D016178:Granulocyte-Macrophage Colony-Stimulating Factor